Wednesday, December 20, 2023
In a recent collaborative venture, InxMed, a clinical-stage biotechnology firm specializing in groundbreaking therapies for drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, have announced a licensing agreement. Under this agreement, InxMed has obtained the rights to utilize Escugen's EZWi-Fit® linker-payload platform for the development of the next generation of tumor-associated antigens (TAAs) targeting ADCs.
The license grants InxMed the exclusive rights for the development, manufacturing, and commercialization of several novel ADC candidate molecules using the EZWi-Fit® platform. InxMed's focus is on advancing next-generation TAAs targeting ADCs, aiming for substantial improvements in efficacy and therapeutic window. The company is concurrently working on solutions to enhance ADC efficacy, including the use of FAK inhibitors to improve ADC penetration and the development of stroma-targeting ADCs to create synergies.
InxMed's strategic positioning aims to revolutionize ADCs by making them more tumor-selective, potent, and offering broad combination potential. A key distinguishing factor will be the incorporation of novel antibodies discovered by InxMed, armed with payloads from the EZWi-Fit® platform. This collaboration sets the stage for the creation of advanced ADCs with enhanced attributes, paving the way for significant advancements in the field.
Source: prnewswire.com
